Annual report [Section 13 and 15(d), not S-K Item 405]

Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)

v3.25.1
Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details)
 12 Months Ended
Apr. 03, 2024
USD ($)
Right
$ / shares
shares
Feb. 27, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Asset acquisition        
Exarafenib milestone asset     $ 3,214,000  
Exarafenib milestone contingent consideration     3,214,000  
Operating lease liabilities     929,000 $ 400,000
Purchase consideration        
Intangible assets     25,909,000  
Operating lease right-of-use assets     319,000 378,000
Allocation of purchase consideration        
Cash and cash equivalents     101,654,000 153,290,000
Prepaid expenses and other current assets     2,076,000 483,000
Exarafenib milestone asset     3,214,000  
Accrued and other liabilities     (5,752,000) (2,768,000)
Operating lease liabilities     (446,000) (54,000)
Long-term operating lease liabilities     (483,000) (335,000)
Less: Gain on the acquisition of Kinnate     (19,316,000)  
Net Income (Loss)     (13,821,000) (40,831,000)
Income and revenues     28,487,000 4,758,000
CVR Agreement | Kinnate CVR holders        
Asset acquisition        
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company $ 30,500,000      
Exarafenib milestone asset 2,900,000   3,200,000  
Contingent consideration from the Exarafenib Sale payable from the Company to the Kinnate CVR Holders under the CVR Agreement 30,500,000      
Exarafenib milestone contingent consideration 2,900,000   3,200,000  
Allocation of purchase consideration        
Exarafenib milestone asset $ 2,900,000   3,200,000  
Exarafenib and related IP | CVR Agreement | Kinnate CVR holders        
Asset acquisition        
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company   $ 30,500,000    
Percentage of further net proceeds from sale   100.00%    
Percentage of net proceeds from any license or other disposition   85.00%    
Exarafenib and related IP | Disposed of by Sale, Not Discontinued Operations | Kinnate        
Asset acquisition        
Contingent consideration from the Exarafenib Sale payable from Pierre Fabre to the Company   $ 30,500,000    
Exarafenib and related IP | Disposed of by Sale, Not Discontinued Operations | Kinnate CVR holders | Kinnate        
Asset acquisition        
Cash consideration received   $ 500,000    
Kinnate        
Asset acquisition        
Asset acquisition, Share price (in dollars per share) | $ / shares $ 2.5879      
Number of non-transferable contractual CVR per share of Kinnate common stock | Right 1      
Exarafenib milestone asset $ 2,922,000      
Operating lease liabilities 800,000      
Purchase consideration        
Closing cash payment 122,646,000      
Estimated fair value of the Exarafenib milestone contingent consideration 2,922,000      
Transaction costs 809,000      
Total purchase consideration $ 126,377,000      
Kinnate common stock tendered | shares 47,232,737      
Total number of underlying shares | shares 2,510,552      
Allocation of purchase consideration        
Cash and cash equivalents $ 142,381,000      
Prepaid expenses and other current assets 3,223,000      
Exarafenib milestone asset 2,922,000      
Accrued and other liabilities (2,009,000)      
Operating lease liabilities (322,000)      
Long-term operating lease liabilities (502,000)      
Net assets acquired 145,693,000      
Less: Gain on the acquisition of Kinnate (19,316,000)      
Total purchase consideration $ 126,377,000      
Severance charges     3,600,000  
Severance charges paid     3,600,000  
Kinnate | Pro forma        
Allocation of purchase consideration        
Net Income (Loss)     $ (13,800,000) $ (25,100,000)